Hoth Therapeutics Receives U.S. Notice of Allowance for Novel Exon-Skipping Therapy Targeting Allergic Diseases
Rhea-AI Summary
Hoth Therapeutics (NASDAQ: HOTH) received a Notice of Allowance from the USPTO on February 12, 2026, for a patent titled "Exon Skipping of FC-Epsilon-RI-Beta and MS4A6A in the Treatment of Allergic Diseases."
The allowed claims cover a dual-mechanism approach—exon skipping in the high-affinity IgE receptor pathway and modulation of MS4A6A—positioning Hoth to expand its immunology IP, pursue partnerships, and strengthen long-term defensibility in allergic and inflammatory disease markets.
Positive
- USPTO issued a Notice of Allowance for the patent on February 12, 2026
- Claims cover a dual-mechanism therapy: FC-epsilon-RI-beta exon skipping + MS4A6A modulation
- Enhances Hoth's immunology IP portfolio and potential partnership/licensing discussions
Negative
- Notice of Allowance is not a granted patent; it moves the application toward formal issuance
- Protection explicitly tied to the United States patent system in this announcement
News Market Reaction
On the day this news was published, HOTH gained 5.16%, reflecting a notable positive market reaction. Argus tracked a peak move of +19.1% during that session. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $807K to the company's valuation, bringing the market cap to $16M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
HOTH was down 1.91% while close peers showed mixed moves: CRIS up 10.2%, PASG down 7.3%, QTTB down 9.04%, and ELEV down 2.28%. With no peers in the momentum scanner and no same‑day peer news, this reaction appears stock‑specific rather than a coordinated biotech move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 10 | Preclinical obesity data | Positive | +10.7% | HT-VA GDNF outperformed semaglutide in a 12-week mouse obesity model. |
| Feb 05 | Crypto clarification | Neutral | -4.0% | Company stated it holds no cryptocurrency assets and reaffirmed trial work. |
| Jan 22 | HT-001 interim data | Positive | +0.0% | Open-label PK cohort showed 100% low-severity response and strong score improvements. |
| Jan 21 | China HT-KIT patent | Positive | -1.9% | China granted key HT-KIT patent, expanding oncology IP protection and partnering potential. |
| Jan 15 | HT-001 Phase 2a start | Positive | +3.4% | IRB approvals for Phase 2a HT-001 trial and disclosure of >$9M cash position. |
Recent HOTH news with strong clinical or preclinical data has often seen positive or flat immediate reactions, while IP and clarification updates have produced mixed to negative moves.
Over the past month, HOTH has reported several catalysts, including positive preclinical obesity data on Feb 10, 2026 that drove a 10.68% gain, and an IR clarification on crypto exposure on Feb 5, 2026 that coincided with a -4.01% move. Earlier, HT-001 clinical results and a China HT-KIT patent in January brought 0% and -1.87% reactions, while a Phase 2a trial start and cash update on Jan 15, 2026 produced a 3.35% rise. Today’s U.S. patent allowance continues the pattern of building IP alongside advancing oncology and obesity programs.
Regulatory & Risk Context
An effective mixed shelf on Form S-3 filed on Nov 14, 2025 allows Hoth to offer up to $50 million in various securities, plus the resale of 1,279,587 shares, providing flexibility for future financings via prospectus supplements.
Market Pulse Summary
The stock moved +5.2% in the session following this news. A strong positive reaction aligns with Hoth’s pattern of sizeable moves on R&D and IP milestones, such as prior double‑digit gains on preclinical data. This patent allowance expands an immunology-focused IP estate while the stock trades well below its 2.115 52-week high and under the 200‑day MA of 1.23. Investors have previously faced dilution risk from a $50 million S‑3 shelf and ATM usage, factors that could temper the durability of large spikes.
Key Terms
exon skipping medical
fc-epsilon-ri-beta medical
ms4a6a medical
ige receptor medical
notice of allowance regulatory
immunomodulatory medical
AI-generated analysis. Not financial advice.
Patent Covers Combination of FC Epsilon RI-Beta Exon Skipping and MS4A6A Modulation — Strengthening Hoth's Immunology IP Portfolio
The Notice of Allowance confirms that the USPTO has allowed all pending claims in the application, moving the patent toward formal issuance.
This patent protects a novel dual-mechanism approach targeting key regulators of allergic and inflammatory responses, positioning Hoth at the forefront of next-generation immunomodulatory therapies.
Strategic Importance
The allowed claims cover methods directed at:
- Exon skipping a critical component of the high-affinity IgE receptor pathway central to allergic disease activation
- Modulation of MS4A6A, a gene associated with immune signaling and inflammatory regulation
- Combination therapeutic strategies designed to reduce hypersensitivity responses at a molecular level
By targeting upstream drivers of allergic inflammation rather than solely treating downstream symptoms, this approach represents a differentiated strategy in a global allergy and immunology market.
Management Commentary
Robb Knie, Chief Executive Officer of Hoth Therapeutics, stated:
"Receiving this Notice of Allowance marks another important milestone in building Hoth's intellectual property portfolio. This novel exon-skipping platform further expands our strategy of developing differentiated, mechanistically targeted therapies for immune-driven diseases. We believe this patent strengthens our competitive positioning and enhances long-term shareholder value."
Intellectual Property Momentum
With this Notice of Allowance, Hoth continues to:
- Expand its proprietary immunology platform
- Build layered patent protection around novel therapeutic mechanisms
- Strengthen potential partnership and licensing discussions
- Increase long-term defensibility in allergic and inflammatory disease markets
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/ .
Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms, or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section titled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance, or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-receives-us-notice-of-allowance-for-novel-exon-skipping-therapy-targeting-allergic-diseases-302686267.html
SOURCE Hoth Therapeutics, Inc.
FAQ
What did Hoth Therapeutics (HOTH) announce on February 12, 2026 about a patent?
What does the allowed patent for HOTH cover and why is it important to investors?
Is the Hoth patent already granted after the February 12, 2026 Notice of Allowance?
How does the allowed claim on exon skipping relate to allergic disease treatment for HOTH shareholders?
Does the February 12, 2026 Notice of Allowance provide international patent protection for Hoth (HOTH)?
